Who makes KW-6356 Y Dose?

KW-6356 Y Dose is developed by Kyowa Kirin Co., Ltd..

Last reviewed 2026-05-15 · How we verify

KW-6356 Y Dose

Kyowa Kirin Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	KW-6356 Y Dose
Sponsor	Kyowa Kirin Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KW-6356 Y Dose CI brief — competitive landscape report
KW-6356 Y Dose updates RSS · CI watch RSS
Kyowa Kirin Co., Ltd. portfolio CI